ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Stephen Carey Sells 2,850 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $73.00, for a total transaction of $208,050.00. Following the completion of the sale, the chief financial officer owned 168,993 shares of the company’s stock, valued at approximately $12,336,489. This trade represents a 1.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Up 0.1%

NASDAQ ANIP traded up $0.10 during trading hours on Wednesday, reaching $72.72. 298,204 shares of the company traded hands, compared to its average volume of 384,030. ANI Pharmaceuticals, Inc. has a 12 month low of $69.58 and a 12 month high of $97.00. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.67 billion, a PE ratio of 15.67, a PEG ratio of 2.41 and a beta of 0.45. The company has a 50 day moving average of $75.50 and a two-hundred day moving average of $78.11.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company’s revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ANIP. Tidal Investments LLC acquired a new stake in ANI Pharmaceuticals in the second quarter worth $248,000. WINTON GROUP Ltd acquired a new position in shares of ANI Pharmaceuticals during the second quarter valued at $4,558,000. Corient Private Wealth LP grew its position in shares of ANI Pharmaceuticals by 95.2% during the second quarter. Corient Private Wealth LP now owns 24,106 shares of the specialty pharmaceutical company’s stock worth $1,995,000 after acquiring an additional 11,754 shares during the last quarter. Amundi grew its position in shares of ANI Pharmaceuticals by 595.5% during the second quarter. Amundi now owns 31,793 shares of the specialty pharmaceutical company’s stock worth $2,632,000 after acquiring an additional 27,222 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth about $1,449,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective for the company. Oppenheimer started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 target price for the company. Finally, Guggenheim dropped their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Three research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $98.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.